September 24th, 2019

Ecrins Therapeutics: results of the pre-IND application to the FDA ahead of the Phase I clinical trial in sarcomas

Ecrins Therapeutics today announced that it successfully completed a pre-IND (Investigational New Drug) package analysis by the U.S. Food and Drug Administration (FDA) regarding its proposed Phase I trial.

As part of Ecrins Therapeutics’s drug development program, in April 2019 the company submitted to the FDA a pre-IND package containing detailed information on the CMC (Chemistry, Manufacturing and Controls), preclinical safety/toxicology, preclinical efficacy data and clinical trial design concerning the lead drug candidate ET-D5. The goal of this submission was to receive the Agency’s opinion on the completeness and relevance of the data that was generated ahead of the official IND application.
The FDA agreed that the completed GLP nonclinical studies were sufficient to support the proposed fist-in-human (FIH) clinical trial in sarcoma and other solid tumors.
The FDA agreed with to the proposed clinical trial design, endpoints and study procedures. The Agency made several important recommendations regarding the drug product, the dosage, the dose-escalation cohorts, the duration of treatment and the inclusion criteria.
Importantly, regarding the patients’ populations, the FDA encouraged the inclusion of young patients ≥12 years of age in the clinical trial (after initial PK and toxicity data have been obtained in adult patients).

September 19th, 2019

Ecrins Therapeutics was selected by BPI France to meet Frédérique Vidal, French Minister of Higher Education, Research, and Innovation during their visit of Grenoble this Thursday the 19th of September for the launch of the “Deeptech Tour” – a partnership between universities and start-ups

Bpifrance organised the first stage of the “Deeptech Tour” on September 19th at the Université Grenoble Alpes. This tour is part of the Deeptech Plan initiated by the Government and put into place by Bpifrance since January 2019. It’s aim is to double within the next 5 years the number of technical start-ups resulting from academic research. The Deeptech Plan strengthens the support provided to Deeptech project initiators and rallys investment and financial agents – notably through the Programme d’Investissements d’Avenir (Program of investments of the future) and the fund for innovation and industry (F2I). Five companies from the Grenoble health industry, including Ecrins Therapeutics, were chosen to meet the Minister and exchange freely in private to collect feedback and expectations of local companies on, amongst other things, the ecosystem of research and innovation.

April 15th, 2019

Ecrins Therapeutics will be present at the 2019 Annual Meeting of the ASCO

Ecrins Therapeutics, represented by Andrei Popov, will be present at the 2019 Annual Meeting of the ASCO (American Society of Clinical Oncology) on May 31 – June 4, 2019 in Chicago. The ASCO Annual Meeting focuses on the latest advances in clinical cancer science and medicine.

April 5th, 2019

Ecrins Therapeutics will present the preliminary results of ET-D5 in a Phase I canine clinical trial focused on sarcomas at the 2019 Forum CLARA in Lyon on April 4th and 5th.

Dr Aurelie JUHEM will present a scientific poster entitled “ET-D5, first-in-class synthetic Protein Phosphatase 1 (PP1) inhibitor for the treatment of sarcomas” on April 5th.
The annual CLARA symposium highlights the innovation in oncology from institutions and companies of the Auvergne Rhône Alpes area.

November 7th, 2018

Ecrins Therapeutics will present the latest data on ET-D5 development at the 2018 Molecular Targets and Cancer Therapeutics Symposium in Dublin

EEcrins Therapeutics, represented by Aurélie Juhem and Benoît Bestgen, will present a scientific poster entitled “ET-D5, first-in-class synthetic Protein Phosphatase 1 (PP1) inhibitor for the treatment of aggressive tumors” at the 2018 Molecular Targets and Cancer Therapeutics Symposium that will be hold in Dublin from the 13th to 16th of November.
The 30th EORTC/AACR/NCI symposium highlights the best cancer targeted therapies from institutions and companies all over the world.

April 30th, 2018

Ecrins Therapeutics : first clinical trial of ET-D5 (in veterinary oncology)

Ecrins Therapeutics is proud to announce today the beginning of the first clinical trial of its lead cancer drug candidate, ET-D5. The clinical trial of Phase I/IIa will be executed in canine patients suffering from high-grade sarcomas.

The trial, launched in January 2018, is carried out in collaboration with Oncology Cancer Research (OCR), a Lille (France)-based company specialized in running clinical trials using innovative cancer drug candidates. The collaborative project DogToMan was certified by the biomedical cluster Lyonbiopôle and is financially supported by the regional communities (Grenoble area) in the frame of the FUI grant mechanism.

DogToMan is an example of the comparative oncology, which (in addition to the veterinary drug development) has a goal to speed up the development of ET-D5 in the human clinic.

April 5th, 2018

Ecrins Therapeutics will be present at the 2018 Annual Meeting of the AACR

Ecrins Therapeutics, represented Andrei Popov and Benoit Bestgen, will be present at the 2018 Annual Meeting of the AACR (American Association for Cancer Research) in Chicago from the 14th to 18th of April. The AACR Annual Meeting highlights the best cancer science and medicine from institutions all over the world. 

June 8th, 2017

Ecrins Therapeutics was selected to present our lead anticancer drug candidate ET-D5 project to the Minister of Health and Solidarity

During her visit to Grenoble, the French Minister of Health and Solidarity Dr. Agnès Buzyn came to meet leading actors of innovation within the Grenoble University business incubator – BIOPOLIS. Ecrins Therapeutics was selected to present our lead anticancer drug candidate ET-D5 project to the Minister and the accompanying delegation including Parliament Member of the Region of Isère -Geneviève Fioraso, the President of University Grenoble Alpes – Lise Dumasy, and representatives of University Grenoble Alpes.

Trained in Hematology, Dr. Buzyn directed for several years a research team at the INSERM (the main public institute of medical research in France) with a focus on the immunology of tumors, based at the Institut Cochin-Paris V.

She also served as President of the INCa (French National Insitute of Cancer).

An active clinical hematologist, Agnès Buzyn continues to see patients at the Saint-Antoine hospital, and is thus confronted daily with the need for new therapies for cancer patients. She congratulated the team of Ecrins Therapeutics for the work it has accomplished, leading to discovery of the molecule ET-D5 and expressed encouragement for the clinical development of our lead drug candidate.

The whole team was delighted to welcome Madame La Ministre in our offices.


January 6th, 2017

Dr Andrei Popov will present ET-D5, the company’s main project, at the 9th Biotech Showcase in San Francisco

The CEO of Ecrins Therapeutics, Dr Andrei Popov,  will present the company’s main project (ET-D5) on Wed, January 11th at 11:30 AM at the 9th Biotech Showcase in San Francisco during one of the most prestigious investor conferences. The theme of the conference: “Where Innovation meets money”. This will take place during biotech’s most impactful week of the year in San Francisco, CA.

November 3rd, 2016

Ecrins Therapeutics pre-selected for its collaborative project focusing on sarcomas at the Trophées de l’Innovation of the Region Rhones-Alpes-Auvergne organized by BrefEco.

On Monday November 7th, Andrei Popov, CEO of Ecrins Therapeutics, will present the “sarcoma” project of the company during the  LAB MEETING of BREF Eco that will be held in Lyon, France.

The event’s goal is to discover and valorize the more advanced and innovative collaborative research programs in Rhone-Alpes.

October 25th, 2016

PRESS RELEASE: Fundraising for Ecrins Therapeutics

Ecrins Therapeutics, a French biotech which is developing an innovative anti-cancer drug candidate, announces the launch of their second fund raising campaign on the French crowdfunding platform – WiSEED.

Established in 2010, Ecrins Therapeutics develops ET-D5, an innovative small molecule for cancer treatment. Stemming from research performed by the founders at the French National Institute of Health and Medical Research (INSERM), ET-D5 has a unique therapeutic target and a double mechanism of action 1) an antiproliferative activity which blocks the multiplication of cancer cells 2) an anti-vascular activity which specifically targets the vessels that supply the tumor.

Ecrins Therapeutics ran their first fundraising session in June 2015 with WiSEED and several Business Angels – allowing them to achieve an important milestone in the development of the drug candidate : performing the obligatory toxicology studies.

These studies allowed us to determine the level of toxicity and learn how the drug candidate behaves inside an organism. The results will serve as a base for defining the doses which will be administered to humans during the clinical trials in order to reduce the risks to a minimum for the first patients,” explains Dr. Aurélie Juhem, COO of Ecrins Therapeutics.

May 30th, 2016

Ecrins Therapeutics at the ASCO Meeting in Chicago

From June 3rd to June 7th, Ecrins Therapeutics was present at the ASCO Annual Meeting, held in Chicago.

Deeply engaged in the developpement of their innovative first-in-class anti-cancer treatment, ET-D5, the French biotech was represented by its CEO Dr. Andrei POPOV.

A major event in the field of oncology, the ASCO Annual Meeting unites over 30,000 of the world’s experts and professionals to “Share Knowledge. Gain Insight.” and to “Improve Cancer Care.”

December 18th, 2015

Recent IP portfolio developments in Asia

Ecrins Therapeutics announces that it has been granted patent number 5 856 086 by the JPO (Japanese Patent Office). “This approval marks a major milestone in the development of our portfolio.” says the CEO of Ecrins Therapeutics, Dr Andrei Popov.

July 1st, 2015

Development of an innovative product for treating sarcomas: a translational study from “Dog to Man”.

Ecrins Therapeutics (project sponsor), in collaboration with Oncovet Clinical Research (a veterinary clinic based in Lille), the Centre Léon Bérard, and the Institut de Génétique et Développement de Rennes launched the Dog to Man project. It is funded in the framework of the 19th call for projects of the FUI (Unique Interministerial Fund).

The selection process involved screening and approval by Lyonbiopôle’s experts, shortly followed by National experts. The goal of the Dog to Man project is to develop an innovative product (ET-D5) aimed at treating sarcomas through a translational clinical study from dog to man.

June 8th, 2015

IP portfolio reinforced in Europe

After a lengthy examination process, the EPO (European Patent Office) has issued patent number EP2542239B1, granting the exclusive rights to use molecules of the ET-D5 family for the treatment of cancer and retinopathies.

April 8th, 2015

Ecrins Therapeutics recognized by the French Ministry of Higher Education and Research (MESR) as a Research Tax Credit (CIR – Crédit Impôt Recherche) entity.

The positive decision of the Ministry entitles our clients who are subject to corporate income tax in France to benefit from a significant tax credit for R&D expenditures outsourced to Ecrins Therapeutics (for example, in the frame of a co-development partnership). The agreement has been granted to Ecrins Therapeutics for five years (2015-2019) and is renewable.

March 30th, 2015

Development of new canine cancer therapy

The transnational programme Eurostars ( which has a 1.4 billion euro budget to support research-performing SME’s to develop innovative products, procedures, and services for competitive advantage – is backing the development of a new antivascular drug to fight cancer in dogs.

Ecrins Therapeutics, the French-based pharmaceutical company lead by Dr Andrei Popov has teamed up with Swiss-based Animal Oncology and Imaging Centre’s Dr Barbara Kaser-Hotz and the UK’s leading private Small Animal Cancer Treatment Centre: VRCC). Dr Susan North of the VRCC is pictured to the left of Dr Popov and Dr Kaser-Hotz at the recent formal signing of the CADAC consortium agreement in Lyon.

March 30th, 2015

Startup Ecrins Therapeutics raises 660 K€ during first round of funding from WiSEED and several Business Angels

Founded by three oncology and cell biology experts – Dr Andrei Popov, Dr Aurélie Juhem, and Professor François Berger – Ecrins Therapeutics discovers and develops innovative cancer therapy products up to clinical proof-of-concept.
Ecrins Therapeutics’ lead compound ET-D5 attacks tumor blood vessels – provoking the death of cancerous cells by depriving them access to a blood source. “New and validated therapeutic targets are rare, and we are thrilled that our lead compound is the first synthetic selective inhibitor – a first-in-class molecule – of protein phosphatase 1 (PP1) developed for treating cancer.” says Andrei Popov, President of Ecrins Therapeutics.

December 12th, 2014

Ecrins Therapeutics is beginning a round of fundraising via the crowdfunding platform WiSEED.

Created in 2010, Ecrins Therapeutics develops an innovative anticancer drug, ET-D5, which is a first-in-class protein phosphatase inhibitor with proven in vivo efficacy. We plan to quickly develop ET-D5 for the treatment of aggressive cancers, such as tumors of the kidney, pancreas, liver, or sarcomas. We are now raising 500 K€ in order to complete the last steps leading to clinical trials, namely regulatory toxicology studies.

November 11th, 2014

Ecrins Therapeutics is pleased to announce the grant of our first U.S. patent

Today, the United States Patent & Trademark Office granted US patent 8883763 B2 for the use of Novel Isoquinolones to prepare therapeutic drugs.
This patent is the first National Patent – granted after application of the initial patent FR 2956816 A1 which was filed in March 2010, followed by a PCT extension WO 2011/107709 A1 which was applied for the following year. This means that the company now holds exclusive worldwide rights to license, develop, and commercialize this family of patents: proof that Ecrins Therapeutics is committed to the creation and reinforcement of its IP portfolio.

December 22nd, 2011

Aurélie Juhem and Andrei Popov, Ecrins Therapeutics co-founders, named laureates of Réseau Entreprendre®

Aurélie Juhem and Andrei Popov, two of the co-founders of Ecrins Therapeutics, became laureates of Réseau Entreprendre® – a national association of entrepreneurs offering financing through a zero-interest, unsecured loan. What’s more, Réseau Entreprendre® gives access to local, national, and international economic networks via business owners who are already members.

October 1st, 2010

Ecrins Therapeutics signs an in-licensing deal for patent number WO2011107709 A1

Ecrins Therapeutics signed an in-licensing agreement with the Joseph Fourier University (UJF), which grants the company exclusive world-wide rights to develop anti-cancer compounds patented (WO2011107709A1) jointly by the UJF, the Institut Curie and the CNRS.

July 21st, 2010

Ecrins Therapeutics is launched

A big step for us: Ecrins Therapeutics is launched.

Commercial Registration Number (In France – RCS, Registre du Commerce et des Sociétés) – 523 783 488. Our address is 5 Avenue du Grand Sablon, Biotech Incubator BIOPOLIS, 38700 La Tronche (Grenoble area).

June 3rd, 2010

Création-Développementt Award : MENRT/ANVAR National Innovation Contest

Ecrins Therapeutics wins in the Life Sciences section at the 2010 MENRT/ANVAR National Innovation Contest. The Création-Dévéloppement Award represents a 220 K€ Grant.

Of special note – the team of Ecrins Therapeutics already won this contest in 2009 in the Emergence category.

June 1st, 2010

Project “CancerDrug” wins the Proof-of-Concept grant from CLARA

Ecrins Therapeutics and its academic partners from the Grenoble Institute of Neurosciences started an ambitious research project aimed at optimizing the in vivo administration of its leading drug candidate: ET-D5. The project “CancerDrug” was selected by the Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA) in the frame of its Proof of Concept program and funded 483 k€ by the Department of Isère, the City of Grenoble, and Grenoble Alpes Métropole.